Immunic
IMUX
Market cap $93.9M

0.9800 USD

+0.0375

3.98%

At close Apr 17, 4:00 PM EDT

After hours

0.9770

-0.0030

0.31%

1 day

3.98%

5 days

10.11%

1 month

-14.04%

3 months

2.83%

6 months

-38.36%

Year to date

-3.92%

1 year

-19.01%

5 years

-88.25%

10 years

-96.35%

About: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Employees: 91

Healthcare Biotechnology

0

Funds holding %

of 7,407 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

104% more call options, than puts

Call options by funds: $859K | Put options by funds: $421K

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

25% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 16

6% more funds holding

Funds holding: 62 [Q3] → 66 (+4) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

5.45% less ownership

Funds ownership: 62.16% [Q3] → 56.7% (-5.45%) [Q4]

45% less capital invested

Capital invested by funds: $92.4M [Q3] → $51.1M (-$41.3M) [Q4]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

512%

upside

Avg. target

$11

1,022%

upside

High target

$17

1,635%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

B. Riley Securities William Woods 0% 1-year accuracy 0 / 4 met price target	512%upside $6	Buy Reiterated	16 Apr 2025
HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 16 / 68 met price target	920%upside $10	Buy Reiterated	15 Apr 2025
D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target	1,635%upside $17	Buy Maintained	10 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about IMUX published over the past 30 days

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

NEW YORK , April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced registered direct offering of 5,666,667 shares of its common stock at a price of $0.90 per share, led by Aberdeen Investments. All securities in the offering were sold by Immunic.

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Proactive Investors

Immunic announces pricing of $5.1M direct offering to support clinical pipeline

Immunic Inc (NASDAQ:IMUX) has priced its $5.1 million registered direct offering led by Aberdeen Investments, selling 5.67 million shares at $0.90 each. The biotechnology company, which is advancing orally administered therapies for chronic inflammatory and autoimmune diseases, expects the financing to close around April 10.

Immunic announces pricing of $5.1M direct offering to support clinical pipeline

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

NEW YORK , April 9, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of a registered direct offering of 5,666,667 shares of its common stock at the market under Nasdaq rules at a price of $0.90 per share, led by Aberdeen Investments. All securities in the offering are being sold by Immunic.

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

NEW YORK , April 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in April: April 5-9: American Academy of Neurology (AAN) 2025 Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in San Diego, California.

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Proactive Investors

Immunic provides MS research update – ICYMI

Immunic Inc (NASDAQ:IMUX) earlier this week provided an update on its multiple sclerosis (MS) drug, vidofludimus calcium, highlighting its potential to address both inflammation and neuroprotection. Dr Hella Kohlhof, Immunic's Chief Scientific Officer, explained that the drug works through a dual mode of action—activating Nurr1 for neuroprotection and inhibiting DHODH to reduce inflammation and Epstein-Barr virus reactivation.

Immunic provides MS research update – ICYMI

Immunic to Participate in Scientific and Investor Conferences in March

NEW YORK , March 3, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March: March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany.

Immunic to Participate in Scientific and Investor Conferences in March

Proactive Investors

Biotechs challenge big pharma with new oral weight loss therapies

With the smash success of glucagon-like peptide-1 (GLP-1) agonists as a treatment for obesity, pharmaceutical giants and emerging biotechnology firms alike are working to develop an equally effective option in the form of pills. The weight loss drug market, projected by Goldman Sachs to reach $130 billion by 2030, represents a significant opportunity for drugmakers.

Biotechs challenge big pharma with new oral weight loss therapies

Proactive Investors

Immunic to highlight vidofludimus calcium's potential as MS therapy at upcoming forum

Immunic Inc (NASDAQ:IMUX) announced that it will present key data for its investigational drug vidofludimus calcium in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025. "Having two poster presentations on vidofludimus calcium at the prestigious ACTRIMS Forum highlights the unique importance of our drug candidate and its promise as a potential new treatment option for multiple sclerosis (MS)," Immunic CEO Dr Daniel Vitt said in a statement.

Immunic to highlight vidofludimus calcium's potential as MS therapy at upcoming forum

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

– Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activation s in Preclinical Models – – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – NEW YORK , Feb. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data on its lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025, taking place from February 27 to March 1, in West Palm Beach, Florida. "Having two poster presentations on vidofludimus calcium at the prestigious ACTRIMS Forum highlights the unique importance of our drug candidate and its promise as a potential new treatment option for multiple sclerosis (MS)," stated Daniel Vitt, Ph.D.

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Proactive Investors

Immunic drug candidate may offer new obesity treatment - ICYMI

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive to discuss the company's latest findings on IMU-856, a drug candidate initially studied for celiac disease. New data suggests that IMU-856 significantly increases endogenous GLP-1 levels in a dose-dependent manner, which could make it a potential oral treatment for obesity.

Immunic drug candidate may offer new obesity treatment - ICYMI

See News Rankings

Charts implemented using Lightweight Charts™